Hormone replacement therapy (HRT) in women after genital cancer (Q34602929)

3 August 2017

1 reference

title

Hormone replacement therapy (HRT) in women after genital cancer (English)

1 reference

Hormone Replacement Therapy

3 August 2017

main subject

1 reference

Adolf E Schindler

1 reference

3 August 2017

publication date

1 April 2002

1 reference

3 August 2017

1 reference

3 August 2017

volume

41 Suppl 1

1 reference

3 August 2017

page(s)

S105-11

1 reference

Hormone replacement therapy in women treated for gynaecological malignancy.

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900018-X

7 January 2021

Hormonal therapy following female genital tract cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900018-X

7 January 2021

Risk of cancer in women receiving hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900018-X

7 January 2021

Long-term surveillance of mortality and cancer incidence in women receiving hormone replacemen therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900018-X

7 January 2021

Case-control study of oestrogen replacement therapy and risk of cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900018-X

7 January 2021

Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900018-X

7 January 2021

Hormonal replacement therapy in patients after cervical cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900018-X

7 January 2021

Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900018-X

7 January 2021

Adjuvant progestagen therapy for the treatment of endometrial cancer: review and meta-analyses of published randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900018-X

7 January 2021

Hormone replacement and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900018-X

7 January 2021

Risk of Endometrial Cancer in Relation to Use of Low-Dose, Unopposed Estrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900018-X

7 January 2021

Therapy with gestagens in hyperplastic changes of the endometrium

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900018-X

7 January 2021

Hormone replacement therapy and endometrial cancer risk: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900018-X

7 January 2021

Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy--long-term follow-up of a Swedish cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900018-X

7 January 2021

Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900018-X

7 January 2021

Progestin Treatment of Atypical Hyperplasia and Well-Differentiated Carcinoma of the Endometrium in Women Under Age 40

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900018-X

7 January 2021

Estrogen replacement therapy following treatment for stage I endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900018-X

7 January 2021

Estrogen replacement therapy: is previously treated cancer a contraindication?

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900018-X

7 January 2021

ERT for survivors of endometrial cancer? A new trial will resolve debate

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900018-X

7 January 2021

Estrogen replacement in surgical stage I and II endometrial cancer survivors

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900018-X

7 January 2021

Megestrol Acetate for the Prevention of Hot Flashes

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900018-X

7 January 2021

Hormone replacement therapy as a risk factor for epithelial ovarian cancer: results of a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900018-X

7 January 2021

Incessant ovulation--a factor in ovarian neoplasia?

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900018-X

7 January 2021

Hormone replacement therapy and risk of epithelial ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900018-X

7 January 2021

Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900018-X

7 January 2021

Estrogen replacement therapy and fatal ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900018-X

7 January 2021

Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900018-X

7 January 2021

Hormone replacement therapy and survival after surgery for ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900018-X

7 January 2021

Estrogen replacement therapy for ovarian carcinoma survivors: A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900018-X

7 January 2021

Progesterone induces apoptosis and up-regulation of p53 expression in human ovarian carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900018-X

7 January 2021

10.1016/S0378-5122(02)00018-X

Identifiers

DOI

1 reference

3 August 2017

1 reference